AI-generated summary
The authors ran a randomized, single-blind pilot trial in 48 people with idiopathic Parkinson's disease, comparing intranasal and transpalatal near-infrared light therapy, alone or combined, with sham. They report that intranasal treatment improved cognitive and motor rating scores, with benefits persisting at one-month follow-up, while the sham group's cognitive score declined. The authors describe these findings as suggesting a possible adjunctive role, with further studies needed.
- Participants
- 40
- Who or what was studied
- Individuals with idiopathic Parkinson's disease; 48 allocated, 40 completed the study
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract describes a pilot study with a small sample and calls for further studies to clarify mechanisms and optimize protocols.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
- Power
- 100 mW
- Total energy
- 60 J, 120 J
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Intranasal photobiomodulation, Montreal Cognitive Assessment, Placebo-controlled, Pilot study, Sham, Oxidative stress, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.